Pulmatrix, Inc., a clinical stage biopharmaceutical company, engages in developing inhaled therapies to address serious pulmonary diseases using its iSPERSE technology. The company's proprietary product pipeline focuses on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with cystic fibrosis, as well as PUR1500, an inhaled product for the treatment of idiopathic pulmonary fibrosis. It is also developing PUR0200, a branded generic in clinical development for chronic obstructive pulmonary disease and other treatments. Pulmatrix, Inc. is based in Lexington, Massachusetts.